DYADIC INTERNATIONAL INC
Business
Dyadic International is a global biotechnology company that develops, manufactures, and commercializes precision-engineered, animal-free recombinant proteins and enzymes using proprietary microbial expression platforms. The company produces recombinant proteins and enzymes for life sciences, food and nutrition, and bio-industrial markets through its proprietary C1 and Dapibus™ platforms. Dyadic operates through direct product sales, distribution partnerships, manufacturing collaborations, and technology licensing agreements that generate revenue from annual licensing fees, milestone payments, development funding, product supply, and revenue-sharing arrangements. The company serves global markets in research, diagnostics, cell culture, nutrition, and industrial biotechnology applications.
Summary from 10-K filed 2026-03-25
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 3 | 3 | 3 | 3 | 2 | |
| Costs of research and development revenue | 600,700 | 1 | — | — | — | |
| Costs of grant revenue | 2 | — | — | — | — | |
| Research and development | 2 | 2 | 3 | 5 | 8 | |
| General and administrative | 6 | 6 | 6 | 6 | 7 | |
| Foreign currency exchange loss | 46,900 | 22,561 | — | — | — | |
| Total costs and expenses | 10 | 9 | 11 | 13 | 17 | |
| Loss from operations | −7 | −6 | −8 | −10 | −15 | |
| Interest income | 284,085 | 456,992 | — | — | — | |
| Gain on sale of Alphazyme | — | 62,642 | 1 | 0 | — | |
| Total other income (expense), net | −171,812 | 91,663 | 1 | 430,420 | 2 | |
| Net loss | −7 | −6 | −7 | −10 | −13 | |
| Basic net loss per common share | −0.23 | −0.2 | −0.24 | −0.34 | −0.47 | |
| Diluted net loss per common share | −0.23 | −0.2 | — | — | — | |
| Basic weighted-average common shares outstanding | 33 | 29 | 29 | 28 | 28 | |
| Diluted weighted-average common shares outstanding | 33 | 29 | — | — | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 5 | 7 | 7 | 6 | 16 | |
| Short-term investment securities | 3 | 3 | — | — | — | |
| Restricted cash | 1 | — | — | — | — | |
| Interest receivable | 35,129 | 24,248 | — | — | — | |
| Accounts receivable | 1 | 237,027 | — | — | — | |
| Prepaid expenses and other current assets | 219,067 | 303,066 | 327,775 | 392,236 | 375,830 | |
| Total current assets | 10 | 10 | 8 | 13 | 21 | |
| Operating lease right-of-use asset, net | 38,535 | 92,211 | 141,439 | 0 | — | |
| Other assets | 10,537 | 10,396 | 10,462 | 6,045 | 6,117 | |
| Total assets | 10 | 10 | 8 | 14 | 21 | |
| Accounts payable | 852,024 | 482,320 | 656,445 | 1 | 2 | |
| Accrued expenses | 967,974 | 970,462 | 1 | 955,081 | 709,560 | |
| Deferred research and development obligations | 2 | 833,813 | 490,113 | 40,743 | 151,147 | |
| Operating lease liability, current portion | 34,621 | 54,249 | 48,059 | 0 | — | |
| Total current liabilities | 4 | 2 | 2 | 2 | 3 | |
| Operating lease liability, net of current portion | — | 34,621 | 88,870 | 0 | — | |
| Total liabilities | 9 | 7 | 2 | 3 | 3 | |
| Commitments and contingencies (Note 4) | — | — | — | — | — | |
| Authorized shares - 5,000,000; none issued and outstanding | — | — | 0 | 0 | 0 | |
| Authorized shares - 100,000,000; issued shares - 48,441,300 and 42,089,301, outstanding shares - 36,187,798 and 29,835,799 as of December 31, 2025, and December 31, 2024, respectively | 48,442 | 42,090 | 41,065 | 40,817 | 40,483 | |
| Additional paid-in capital | 114 | 107 | 105 | 103 | 101 | |
| Treasury stock shares held at cost - 12,253,502 | −19 | −19 | −19 | −19 | −19 | |
| Accumulated deficit | −93 | −86 | −80 | −73 | −64 | |
| Total stockholders equity | 1 | 2 | 6 | 11 | 18 | |
| Total liabilities and stockholders equity | 10 | 10 | 8 | 14 | 21 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation expense | 930,183 | 1 | 1 | 2 | 2 | |
| Amortization of held-to-maturity securities, net | −24,169 | −71,057 | −53,032 | 33,790 | — | |
| Amortization of debt issuance costs | 48,697 | 63,021 | 0 | — | — | |
| Gain on investment in Alphazyme | — | −60,977 | — | — | — | |
| Foreign currency exchange loss | 46,901 | 22,561 | 38,418 | 49,918 | 96,893 | |
| Interest receivable | −10,881 | −14,165 | 48,202 | 36,090 | 17,872 | |
| Accounts receivable | −846,964 | 219,425 | −141,332 | −83,265 | −31,792 | |
| Prepaid expenses and other current assets | 83,964 | 24,742 | 64,902 | −13,925 | −95,366 | |
| Operating lease assets and liabilities, net | −573 | 1,169 | −4,510 | 0 | — | |
| Accounts payable | 314,451 | −180,182 | −651,168 | −248,128 | 549,562 | |
| Accrued expenses | 229,132 | 252,664 | 444,269 | 245,521 | 219,824 | |
| Accrued interest | −20,000 | 80,000 | — | — | — | |
| Accrued interest - related party | 14,627 | 27,173 | — | — | — | |
| Deferred research and development obligations | 897,039 | 343,700 | 449,370 | −110,404 | 28,131 | |
| Net cash used in operating activities | −6 | −4 | −7 | −8 | −11 | |
| Purchases of held-to-maturity investment securities | −6 | −7 | −3 | −10 | −11 | |
| Proceeds from maturities of investment securities | 6 | 5 | 9 | 8 | 15 | |
| Proceeds from the sale of investment in Alphazyme | — | 60,977 | 1 | 0 | — | |
| Net cash provided by (used in) investing activities | 82,085 | −2 | 7 | −2 | 5 | |
| Proceeds from public offering, net of offering costs | 5 | — | — | — | — | |
| Proceeds from issuance of convertible notes, net of issuance costs | — | 4 | — | — | — | |
| Proceeds from issuance of convertible notes, net of issuance costs - related party | — | 2 | — | — | — | |
| Proceeds from exercise of options | 24,249 | 24,251 | 0 | 543,591 | 1 | |
| Net cash provided by financing activities | 5 | 6 | 0 | 543,591 | 1 | |
| Effect of exchange rate changes on cash | 1,941 | −5,796 | −2,385 | −44,744 | −63,262 | |
| Net decrease in cash, cash equivalents and restricted cash | −653,251 | −8,278 | 720,756 | −10 | −5 | |
| Vesting of restricted stock units | 231,621 | 340,334 | 342,186 | 0 | — | |
| Conversion of convertible notes | — | 910,000 | 0 | — | — | |
| Cash paid for interest | 412,573 | 257,778 | 0 | — | — | |
| Fair value of warrants issued in connection with the offering | 168,881 | — | — | — | — | |
| Purchase and assignment of convertible note by related party | 1 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is DYADIC INTERNATIONAL INC's CIK number?
DYADIC INTERNATIONAL INC's SEC CIK number is 0001213809 (1213809). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find DYADIC INTERNATIONAL INC's SEC filings?
All of DYADIC INTERNATIONAL INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did DYADIC INTERNATIONAL INC last report earnings?
DYADIC INTERNATIONAL INC (DYAI) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-022727). This is DYADIC INTERNATIONAL INC's most recent earnings filing of record — not a forecast of its next earnings date.
What is DYADIC INTERNATIONAL INC's most recent earnings 8-K?
DYADIC INTERNATIONAL INC's latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001493152-26-022727. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View DYADIC INTERNATIONAL INC's latest earnings 8-K →
Look up any company's CIK number →